☰
  • Home
  • Blog
  • Policy Papers
  • Analysis
  • Report Cards
  • Summits
  • You’re Invited
Logo
  • Blog
  • Policy Papers
  • Report Cards
  • Analysis
  • Summits

ICER Misses the Numbers That Matter

March 18, 2020

The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.

View the Graphic

Tags: Respiratory

Categorized in: Analysis

Recent Blog Posts

Why Don’t Insurers Take Obesity Seriously?  June 30, 2022
Feds Poised to Take a Hard Look at Pharmacy Benefit Managers June 28, 2022
Federal Court Upholds West Virginia Law that Reigns in “Bad Drug” Ads June 24, 2022

2020 K Street NW, Suite 505 Washington, DC 20006 (202) 964-2624

About Us Archive

© 2022 Copyright Institute for Patient Access